Remove Big Data Remove Business Development Remove Life Science
article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

David Clifton is professor of clinical machine learning in the Department of Engineering Science of the University of Oxford. His research focuses on the development of big data machine learning for tracking the health of complex systems. Mark holds a PhD in biomedicine, and an MSc in biostatistics.

article thumbnail

Empowering rare disease patient advocacy organisations with data

pharmaphorum

In 2021, Komodo acquired two companies: Mavens, a developer of cloud-based software used for speciality biotech and pharma companies, and Breakaway Partners, a market access software company targeting the life sciences industry. He oversees operations, including business development, sales and marketing, and people.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Using technology to reassess the clinical trial landscape

pharmaphorum

He oversees operations, including business development, sales and marketing, and people. He also serves as an executive advisor to Reify Health, Heads Up Health , and other healthcare/healthtech start-ups focused on big data, SaaS, healthcare IT (HIT), and predictive analytics to improve patient outcomes.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. 2022 Revenue: In 2022, Merck KGaA (Life Science and Healthcare divisions only) had an annual revenue of €18.22

Sales 85